GSK Acquisition Of Corixa Means End To Royalty Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK agrees to pay $300 mil. for Corixa in an M&A play to pick up the biotech's adjuvant technology. The deal will allow GSK to avoid paying adjuvant therapy royalty payments. Corixa's technology is used in GSK's high-profile Cervarix HPV vaccine.
You may also be interested in...
Cervarix Reimbursement Will Be Key Challenge For Adoption, GSK Says
GlaxoSmithKline plans to submit a BLA for the human papillomavirus vaccine by year-end.
Cervarix Reimbursement Will Be Key Challenge For Adoption, GSK Says
GlaxoSmithKline plans to submit a BLA for the human papillomavirus vaccine by year-end.
Corixa Sells Bexxar Rights To GSK As Part Of Restructuring
The cost-cutting effort includes the elimination of 160 positions at the company's South San Francisco and Seattle operations, Corixa says. Copromotion partner GlaxoSmithKline will take over Bexxar development and marketing responsibilities effective Dec. 31.